SCHEMBL19732832

SCHEMBL19732832

C=C(CO)Cc1cc(CC)c(O)c(C(C)(C)C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 2/20 0.55
ALDH1A1 P00352 7/20 0.41
TSHR P16473 4/20 0.41
KMT2A Q03164 4/20 0.41
LMNA P02545 4/20 0.41
MAPK1 P28482 3/20 0.41
HIF1A Q16665 3/20 0.41
MEN1 O00255 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
BLM P54132 2/20 0.41
ATM Q13315 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
GMNN O75496 1/20 0.41
GABBR2 O75899 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19732830 0.87 ALDH1A1 (0.53) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL19732828 0.81 CYP2C9 (0.49) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL10822034 0.80 HSPA5 (0.66) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL57329 0.80 HSPA5 (0.82) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL7796135 0.80 HSPA5 (0.60) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL2349337 0.79 HSPA5 (0.73) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL3809095 0.78 HSPA5 (0.62) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL18902069 0.77 HSPA5 (0.71) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL10821851 0.76 HSPA5 (0.64) HSPA5ALDH1A1TSHRKMT2ALMNA
SCHEMBL10822059 0.76 HSPA5 (0.64) HSPA5ALDH1A1TSHRKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3260461-B1 PHOSPHITE COMPOUND, METHOD FOR PRODUCING THE SAME AND USES THEREOF SUMITOMO CHEMICAL CO (JP) 2019-10-16 EP disclosed
US-9902747-B2 Phosphite compound, method for producing the same and uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-27 US disclosed
US-20180002359-A1 PHOSPHITE COMPOUND, METHOD FOR PRODUCING THE SAME AND USES THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-04 US disclosed
EP-3260461-A1 PHOSPHITE COMPOUND, METHOD FOR PRODUCING THE SAME AND USES THEREOF Sumitomo Chemical Company, Ltd. (JP) 2017-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002359-A1 PHOSPHITE COMPOUND, METHOD FOR PRODUCING THE SAME AND USES THEREOF PHOSPHO1, AGPS, PLCG1 HSPA5 4712/4885ALDH1A1 3839/4885TSHR 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.